Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review. Read more about Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review.
PMS2 monoallelic mutation carriers: the known unknown. Read more about PMS2 monoallelic mutation carriers: the known unknown.
Key emerging themes for assessing the cost-effectiveness of reporting incidental findings. Read more about Key emerging themes for assessing the cost-effectiveness of reporting incidental findings.
Assessing multilevel determinants of adoption and implementation of genomic medicine: an organizational mixed-methods approach. Read more about Assessing multilevel determinants of adoption and implementation of genomic medicine: an organizational mixed-methods approach.
Whole-exome sequencing in undiagnosed genetic diseases: interpreting 119 trios. Read more about Whole-exome sequencing in undiagnosed genetic diseases: interpreting 119 trios.
Maternal cell-free DNA-based screening for fetal microdeletion and the importance of careful diagnostic follow-up. Read more about Maternal cell-free DNA-based screening for fetal microdeletion and the importance of careful diagnostic follow-up.
Reporting genomic secondary findings: ACMG members weigh in. Read more about Reporting genomic secondary findings: ACMG members weigh in.
Mutations in NGLY1 cause an inherited disorder of the endoplasmic reticulum-associated degradation pathway. Read more about Mutations in NGLY1 cause an inherited disorder of the endoplasmic reticulum-associated degradation pathway.
Delivery of clinical genetic consultative services in the Veterans Health Administration. Read more about Delivery of clinical genetic consultative services in the Veterans Health Administration.
The economic value of personalized medicine tests: what we know and what we need to know. Read more about The economic value of personalized medicine tests: what we know and what we need to know.
